Maternus-Kliniken Aktiengesellschaft (MAK.DE)
EUR 1.49
(-2.61%)
EUR 1.49
(-2.61%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.71 Million EUR | -275.91% |
| 2022 | 1.71 Million EUR | -79.08% |
| 2021 | 14.96 Million EUR | 37.3% |
| 2020 | 13.21 Million EUR | 51.29% |
| 2019 | 8.96 Million EUR | -15.42% |
| 2018 | 8.53 Million EUR | -24.2% |
| 2017 | 11.37 Million EUR | 3.6% |
| 2016 | 11.03 Million EUR | -17.55% |
| 2015 | 13.43 Million EUR | -64.62% |
| 2014 | 37.98 Million EUR | 12699.0% |
| 2013 | 2.17 Million EUR | -110.16% |
| 2012 | 2.94 Million EUR | -67.15% |
| 2011 | 8.95 Million EUR | -18.36% |
| 2010 | 10.97 Million EUR | -0.26% |
| 2009 | 11 Million EUR | 0.11% |
| 2008 | 10.98 Million EUR | 21.41% |
| 2007 | 9.05 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 7.22 Million EUR | 0.0% |
| 2023 Q3 | -530.83 Thousand EUR | -158.33% |
| 2023 Q4 | -1.02 Million EUR | -93.99% |
| 2023 FY | - EUR | -275.91% |
| 2023 Q1 | -502 Thousand EUR | 73.37% |
| 2023 Q2 | 910 Thousand EUR | 281.27% |
| 2022 FY | - EUR | -79.08% |
| 2022 Q2 | 1.04 Million EUR | -41.15% |
| 2022 Q3 | -2.68 Million EUR | -357.18% |
| 2022 Q1 | 1.77 Million EUR | -77.44% |
| 2022 Q4 | -1.88 Million EUR | 29.8% |
| 2021 Q1 | 3.5 Million EUR | -53.72% |
| 2021 Q3 | 1.34 Million EUR | -53.59% |
| 2021 Q2 | 2.9 Million EUR | -17.13% |
| 2021 Q4 | 7.86 Million EUR | 482.95% |
| 2021 FY | - EUR | 37.3% |
| 2020 Q1 | 2.77 Million EUR | -15.29% |
| 2020 Q2 | 2.82 Million EUR | 1.57% |
| 2020 FY | - EUR | 51.29% |
| 2020 Q3 | 1.74 Million EUR | -38.06% |
| 2020 Q4 | 7.58 Million EUR | 333.8% |
| 2019 Q3 | -611.83 Thousand EUR | -118.63% |
| 2019 Q2 | 3.28 Million EUR | 16.39% |
| 2019 Q1 | 2.82 Million EUR | 171.69% |
| 2019 FY | - EUR | -15.42% |
| 2019 Q4 | 3.27 Million EUR | 635.93% |
| 2018 Q4 | 1.03 Million EUR | 0.0% |
| 2018 Q2 | 1.36 Million EUR | -22.99% |
| 2018 FY | - EUR | -24.2% |
| 2018 Q1 | 1.77 Million EUR | -8.61% |
| 2018 Q3 | 1.03 Million EUR | -23.92% |
| 2017 Q2 | 2.28 Million EUR | -9.67% |
| 2017 Q3 | 1.93 Million EUR | -15.05% |
| 2017 Q4 | 1.93 Million EUR | 0.0% |
| 2017 Q1 | 2.52 Million EUR | -16.54% |
| 2017 FY | - EUR | 3.6% |
| 2016 Q4 | 3.02 Million EUR | 0.0% |
| 2016 FY | - EUR | -17.55% |
| 2016 Q2 | 2.44 Million EUR | 0.12% |
| 2016 Q3 | 3.02 Million EUR | 24.02% |
| 2016 Q1 | 2.43 Million EUR | -62.51% |
| 2015 Q4 | 6.5 Million EUR | 168.25% |
| 2015 FY | - EUR | -64.62% |
| 2015 Q3 | 2.42 Million EUR | 10.53% |
| 2015 Q2 | 2.19 Million EUR | -0.5% |
| 2015 Q1 | 2.2 Million EUR | -93.15% |
| 2014 Q4 | 32.19 Million EUR | 1084.19% |
| 2014 Q3 | 2.71 Million EUR | 96.32% |
| 2014 Q2 | 1.38 Million EUR | -0.36% |
| 2014 Q1 | 1.39 Million EUR | 165.91% |
| 2014 FY | - EUR | 12699.0% |
| 2013 Q4 | -2.1 Million EUR | -258.81% |
| 2013 Q3 | 1.32 Million EUR | 308.62% |
| 2013 Q2 | 325 Thousand EUR | 105.7% |
| 2013 Q1 | 158 Thousand EUR | 104.3% |
| 2013 FY | - EUR | -110.16% |
| 2012 Q1 | 1.47 Million EUR | -59.78% |
| 2012 Q2 | 1.11 Million EUR | -24.63% |
| 2012 Q3 | 3.82 Million EUR | 243.54% |
| 2012 FY | - EUR | -67.15% |
| 2012 Q4 | -3.67 Million EUR | -196.08% |
| 2011 Q4 | 3.67 Million EUR | -99.9% |
| 2011 Q3 | 3.65 Billion EUR | 227414.5% |
| 2011 Q2 | 1.6 Million EUR | 1.64% |
| 2011 FY | - EUR | -18.36% |
| 2011 Q1 | 1.58 Million EUR | -48.54% |
| 2010 FY | - EUR | -0.26% |
| 2010 Q4 | 3.07 Million EUR | -99.91% |
| 2010 Q3 | 3.5 Billion EUR | 105677.25% |
| 2010 Q2 | 3.31 Million EUR | 126.83% |
| 2010 Q1 | 1.46 Million EUR | 0.0% |
| 2009 FY | - EUR | 0.11% |
| 2008 FY | - EUR | 21.41% |
| 2007 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | 2.93 Billion EUR | 99.839% |
| Fresenius SE & Co. KGaA | 2.73 Billion EUR | 99.828% |
| LIMES Schlosskliniken AG | 854.98 Thousand EUR | -451.474% |
| M1 Kliniken AG | 21.79 Million EUR | 78.364% |
| MEDICLIN Aktiengesellschaft | 101.26 Million EUR | 95.344% |
| RHÖN-KLINIKUM Aktiengesellschaft | 116.58 Million EUR | 95.956% |
| VITA 34 AG | 5.8 Million EUR | 18.791% |